IL13 and colitis: Similarly, when IL-13 downstream effector functions are blocked, via the elimination of NKT cells or by using an IL-13 receptor α2-fusion protein, the development of colitis is prevented [10], whereas antibodies against IL-12 severely aggravate the disease [11].